$FCSC low S/S breakout $1.00 Nasdaq CM Looked at
Post# of 36
Posted On: 11/27/2016 5:45:52 PM
$FCSC low S/S breakout $1.00
Nasdaq CM
Looked at last week $0.82
Website
10-Q 11/3/16
O/S 43,978,326
Headlines
and filings
Fibrocell Science, Inc., an autologous cell and gene therapy company, focuses on discovering and developing therapies for diseases affecting the skin, connective tissues, and joints in the United States. The company offers LAVIV (azficel-T), a biological product that uses the companys proprietary autologous fibroblast technology for the enhancement of the appearance of nasolabial fold wrinkles in adults. It also develops azficel-T, which is in Phase II clinical trial for the treatment of vocal cord scarring resulting in chronic or severe dysphonia. The companys gene-therapy product candidates include FCX-007 that is in pre-clinical development to treat recessive dystrophic epidermolysis bullosa; FCX-013, which is in pre-clinical development for the treatment of linear scleroderma; and gene-therapy program that is in research Phase to treat arthritis. It has collaboration agreement with Intrexon Corporation for the development of FCX-007, FCX-013, and products for the treatment of chronic inflammation and degenerative diseases of human joints; and The Regents of the University of California to focus on media that promotes genomic stability in induced pluripotent stem cell cultures. The company was formerly known as Isolagen, Inc. and changed its name to Fibrocell Science, Inc. in September 2009. Fibrocell Science, Inc. was incorporated in 1992 and is based in Exton, Pennsylvania.
Nasdaq CM
Looked at last week $0.82
Website
10-Q 11/3/16
O/S 43,978,326
Headlines
and filings
Fibrocell Science, Inc., an autologous cell and gene therapy company, focuses on discovering and developing therapies for diseases affecting the skin, connective tissues, and joints in the United States. The company offers LAVIV (azficel-T), a biological product that uses the companys proprietary autologous fibroblast technology for the enhancement of the appearance of nasolabial fold wrinkles in adults. It also develops azficel-T, which is in Phase II clinical trial for the treatment of vocal cord scarring resulting in chronic or severe dysphonia. The companys gene-therapy product candidates include FCX-007 that is in pre-clinical development to treat recessive dystrophic epidermolysis bullosa; FCX-013, which is in pre-clinical development for the treatment of linear scleroderma; and gene-therapy program that is in research Phase to treat arthritis. It has collaboration agreement with Intrexon Corporation for the development of FCX-007, FCX-013, and products for the treatment of chronic inflammation and degenerative diseases of human joints; and The Regents of the University of California to focus on media that promotes genomic stability in induced pluripotent stem cell cultures. The company was formerly known as Isolagen, Inc. and changed its name to Fibrocell Science, Inc. in September 2009. Fibrocell Science, Inc. was incorporated in 1992 and is based in Exton, Pennsylvania.
(0)
(0)